Medicus Pharma’s (MDCX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Medicus Pharma (NASDAQ:MDCX) in a report published on Tuesday,Benzinga reports. The firm currently has a $27.00 price objective on the stock.

A number of other brokerages have also weighed in on MDCX. Weiss Ratings restated a “sell (e+)” rating on shares of Medicus Pharma in a research report on Wednesday, October 8th. Zacks Research upgraded Medicus Pharma to a “hold” rating in a research report on Monday, September 15th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $23.50.

Medicus Pharma Stock Performance

Shares of MDCX stock opened at $2.41 on Tuesday. Medicus Pharma has a 52-week low of $1.79 and a 52-week high of $8.94. The firm has a market capitalization of $42.95 million and a PE ratio of -1.80. The stock has a fifty day simple moving average of $2.27 and a two-hundred day simple moving average of $3.20.

Medicus Pharma (NASDAQ:MDCX) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). On average, sell-side analysts forecast that Medicus Pharma will post -1.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in MDCX. Armistice Capital LLC bought a new position in shares of Medicus Pharma in the 1st quarter valued at about $4,710,000. Interchange Capital Partners LLC lifted its holdings in shares of Medicus Pharma by 14.0% in the 1st quarter. Interchange Capital Partners LLC now owns 1,661,871 shares of the company’s stock valued at $6,182,000 after acquiring an additional 204,706 shares during the last quarter. Guyasuta Investment Advisors Inc. bought a new position in shares of Medicus Pharma in the 2nd quarter valued at about $230,000. Private Advisor Group LLC bought a new position in shares of Medicus Pharma in the 1st quarter valued at about $211,000. Finally, SeaCrest Wealth Management LLC bought a new position in shares of Medicus Pharma in the 2nd quarter valued at about $139,000.

About Medicus Pharma

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.